# Novartis account plan

> Novartis is an innovative medicines company with 2025 net sales of USD 54.5 billion, 75 267 employees and products sold in about 120 countries.

## At a glance

Novartis researches, develops, manufactures and sells innovative medicines, focused on four therapeutic areas (cardiovascular, renal and metabolic; immunology; neuroscience; oncology) and on chemistry, biotherapeutics, radioligand therapy, xRNA and cell and gene therapy platforms. It sells to wholesalers, retailers, health systems, government agencies and pharmacy benefit managers in approximately 120 countries, with the US, China, Germany and Japan as priority markets. In 2025 net sales from continuing operations were USD 54.5 billion (+8%) and net income USD 14.0 billion, with 75 267 full-time equivalents at December 31, 2025. Headquartered in Basel, it has been a pure-play medicines company since the Sandoz spin-off in October 2023; Giovanni Caforio is Chair and Vas Narasimhan CEO.

## Business units

- **Oncology** (about 31% of 2025 net sales (USD 16.8 billion)): The largest therapeutic area, up 18% in 2025, driven by Kisqali, Pluvicto, Scemblix and Fabhalta. Q2 2026 sales rose 35% to USD 4 515 million, offsetting generic erosion of Promacta and Tasigna.
- **Immunology** (about 19% of 2025 net sales (USD 10.3 billion)): Led by Cosentyx (USD 6.7 billion in 2025), plus Ilaris, Xolair and the newly approved oral BTK inhibitor Rhapsido. Q2 2026 sales were USD 2 780 million (+9%), with Xolair under biosimilar pressure.
- **Cardiovascular, renal and metabolic** (about 16% of 2025 net sales (USD 9.0 billion)): Entresto lost US exclusivity in Q3 2025 and fell 50% in Q2 2026, while Leqvio grew 61% and is registered in 109 countries. The pipeline adds abelacimab, pacibekitug and pelacarsen.
- **Neuroscience** (about 11% of 2025 net sales (USD 6.0 billion)): Grew 26% in 2025, led by Kesimpta in multiple sclerosis (USD 4.4 billion) and the Zolgensma gene therapy, with the intrathecal Itvisma launched in 2025.
- **Established brands** (about 23% of 2025 net sales (USD 12.5 billion)): Mature and off-patent products plus contract manufacturing; sales fell 7% in 2025 and 12% in Q2 2026, while contract manufacturing grew 71% in Q2 2026.
- **US commercial unit** (43% of 2025 net sales (USD 23.3 billion)): Headquartered in East Hanover, New Jersey and led by Victor Bulto; sales grew 10% in 2025 but fell 5% in Q2 2026 on Entresto and Promacta generics.
- **International commercial unit** (USD 31.2 billion of 2025 net sales): Covers Europe (USD 16.7 billion), Asia/Africa/Australasia and Canada and Latin America, led by Patrick Horber; China reached USD 4.2 billion in 2025.

## Strategic priorities

- **Accelerate growth with high-value medicines**: Novartis cites more than 30 potential high-value medicines and 15 submission-enabling readouts over two years, and confirms a 5-6% (cc) annual sales growth outlook through the end of the decade.
- **Operational excellence and cost**: The company aims to simplify processes and reduce costs; management says SG&A is where it can do more, focusing on third-party spend of upwards of $10 billion, and a Lean Digital Core programme modernises processes in Germany, UK, Netherlands and US.
- **AI across the value chain**: Strengthening foundations includes artificial intelligence capabilities, with partnerships such as Isomorphic Labs; the CEO aims to cut the 12-14 years from target to licence by 2 to four years.
- **Platform technologies**: Radioligand therapy, xRNA and cell and gene therapy are the three advanced platforms, with siRNA delivery beyond the liver the logic of the Avidity acquisition.
- **Priority markets**: The US, China, Germany and Japan are expected to account for most of the growth in global healthcare spending through 2030; China grew 13% in H1 2026 to USD 2.5 billion.

## Latest results

In Q2 2026 net sales were USD 14 408 million (+3%, +1% cc), the return to growth after the US Entresto generic entry, with core operating income flat at USD 5 940 million and a 41.2% core margin. Net income fell 19% to USD 3 257 million on a higher tax rate. For H1 2026 net sales were USD 27 521 million (+1%, -2% cc) and core operating income USD 10.8 billion (-6%). Full-year 2026 guidance was reaffirmed: net sales up low single digits and core operating income down low single digits, with H2 sales expected to grow mid-single digits.

## Investments and deals

- **Avidity Biosciences**: Closed on February 27, 2026 for about USD 12.0 billion in cash, adding RNA therapeutics for DM1, FSHD and DMD; del-zota is expected to launch in H1 2027.
- **2026 bolt-on deals**: Pikavation Therapeutics (USD 1.8 billion cash plus milestones, May 2026) and Excellergy (USD 0.9 billion plus milestones, June 2026); the M&A strategy favours steady deals in the sub-$2 billion range.
- **2025 acquisitions**: Anthos Therapeutics (USD 0.8 billion), Regulus Therapeutics (USD 0.8 billion) and Tourmaline Bio (USD 1.2 billion) in 2025.
- **US manufacturing**: A USD 23 billion US investment over five years, alongside capacity expansion in cell culture, radioligand therapy, biopharmaceutical and small-molecule manufacturing across 31 manufacturing sites.
- **Shareholder returns**: USD 9.1 billion of dividends and USD 2.1 billion of buybacks in H1 2026; USD 5.6 billion remains in the up-to USD 10 billion programme, to finish by end 2027.

## Challenges and risks

- **Loss of exclusivity**: US generics hit Entresto, Promacta and Tasigna; a June 2026 Delaware court ruling went against Lutathera patents, which Novartis has appealed.
- **US pricing pressure**: Risks include the Inflation Reduction Act, the May 2025 most-favored-nation executive order and the December 2025 agreement with the US administration.
- **Higher leverage**: Net debt rose to USD 39.4 billion at June 30, 2026 after the Avidity deal, from USD 21.9 billion at end 2025.
- **Launch execution in advanced technologies**: Launching cell and gene and radioligand therapies and keeping pace with AI are named R&D and commercial execution risks.

## What leadership says

> "Novartis delivered strong performance across our priority brands and launches while advancing the pipeline, allowing us to return to growth in the second quarter." — Vas Narasimhan, Chief Executive Officer, Q2 2026 results conference call, 2026-07-21

> "Any points we give now, we won't be able to get back in the future." — Vas Narasimhan, Chief Executive Officer, Q2 2026 results conference call, on Rhapsido gross-to-net, 2026-07-21

> "what I observed was we were misallocating capital" — Vas Narasimhan, Chief Executive Officer, a16z interview with Jorge Conde, 2026-03-13, on the move from conglomerate to pure play


## Where a supplier can help

- **Third-party spend and SG&A**: Management names SG&A, and third-party spend of upwards of $10 billion, as where it can do more; procurement, outsourcing and productivity suppliers fit the operational excellence priority.
- **AI and digital tooling**: AI across the value chain and the Lean Digital Core programme open room for data, AI, ERP and clinical-trial technology vendors, for example around clinical-trial data entry, which the CEO says a startup should fix.
- **Manufacturing and supply chain build-out**: The USD 23 billion US investment and capacity expansion in radioligand therapy and cell culture create needs for engineering, equipment, isotopes logistics and on-time delivery services.
- **Integration of acquired biotechs**: Avidity, Pikavation, Excellergy and the 2025 deals need integration, CMC and clinical development support as R&D spend keeps rising on acquired assets.
- **Launch support**: Launches such as Rhapsido, Itvisma, ianalumab and del-zota, and possible field force investment for abelacimab and pacibekitug, call for commercial, market access and direct-to-patient platform partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Novartis Annual Report 2025 (Form 20-F content)](https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2025.pdf)

Annual report · 2026-02-04

- Novartis is a "pure-play" innovative medicines company headquartered in Basel: 2025 net sales from continuing operations USD 54.5 billion (+8%, +8% cc), net income USD 14.0 billion, 75 267 full-time equivalent employees, products sold in approximately 120 countries, more than 300 million patients reached.
- Four core therapeutic areas: oncology (USD 16.8 billion, +17% cc), immunology (USD 10.3 billion, +10% cc), cardiovascular, renal and metabolic (USD 9.0 billion, +3% cc) and neuroscience (USD 6.0 billion, +25% cc); established brands shrank to USD 12.5 billion (-7% cc).
- Growth drivers: Kisqali USD 4.8 billion (+57% cc), Kesimpta USD 4.4 billion (+36% cc), Cosentyx USD 6.7 billion (+8% cc), Pluvicto USD 2.0 billion (+42% cc), Scemblix USD 1.3 billion (+85% cc), Leqvio USD 1.2 billion (+57% cc, blockbuster status); generic competition cost 6 percentage points of growth (Entresto, Promacta, Tasigna, Lucentis).
- Profitability: operating income USD 17.6 billion (+25% cc, 32.4% of sales); core operating income USD 21.9 billion with a 40.1% core margin, reached two years ahead of the 2027 guidance; free cash flow USD 17.6 billion; proposed dividend CHF 3.70 (+5.7%).
- US is 43% of sales (USD 23.3 billion, +10%); Europe 31%; emerging growth markets USD 14.0 billion including USD 4.2 billion in China. Priority markets: US, China, Germany, Japan.
- Strategy: three priorities (deliver high-value medicines, embed operational excellence, strengthen foundations) and three advanced platforms (radioligand therapy, xRNA, cell and gene therapy) on top of chemistry and biotherapeutics; long-term sales growth outlook of 5-6% (cc) per year through the end of the decade.
- Bolt-on M&A: Anthos Therapeutics (abelacimab), Regulus Therapeutics, Tourmaline Bio (pacibekitug) closed in 2025; Avidity Biosciences agreed for about USD 12 billion in cash (pending at publication, expected to close H1 2026); 17 BD&L/M&A deals signed in 2025.
- USD 23 billion investment in the US over five years to enable end-to-end US production of all key therapies; December 2025 voluntary pricing agreement with the US administration (comparable launch prices across high-income countries, GENEROUS Medicaid model, direct-to-patient platforms) and an expected three-year relief from pharmaceutical tariffs.
- Main risks: pricing and reimbursement pressure (IRA, most-favored-nation pricing), loss of exclusivity (Entresto, Promacta, Tasigna in the US), R&D failure, cybersecurity, supply continuity, tariffs and FX.

### [Novartis Second Quarter and Half Year 2026 Condensed Interim Financial Report](https://www.novartis.com/sites/novartis_com/files/q2-2026-interim-financial-report-en.pdf)

Interim report · 2026-07-21

- Q2 2026 net sales USD 14.4 billion (+3%, +1% cc): volume +18 points offset by -14 points from generic competition and -3 points pricing; US sales USD 6.0 billion (-5%), rest of world USD 8.5 billion (+8%).
- H1 2026 net sales USD 27.5 billion (+1%, -2% cc); core operating income USD 10.8 billion (-6%, -7% cc), core margin 39.4%; free cash flow USD 8.9 billion (-9%).
- Q2 core operating income USD 5.9 billion (0% cc), core margin 41.2%; operating income USD 4.8 billion; net income USD 3.3 billion (-19%) on higher taxes and interest.
- Entresto US generics: Q2 Entresto sales USD 1 181 million (-50%); Promacta/Revolade -64% and Tasigna -57%.
- Growth drivers: Kisqali USD 1 695 million (+44%), Kesimpta USD 1 424 million (+32%), Pluvicto USD 651 million (+43%), Scemblix USD 562 million (+89%), Leqvio USD 480 million (+61%, NRDL inclusion in China), Cosentyx USD 1 824 million (+12%), Rhapsido USD 64 million.
- Avidity Biosciences acquired on February 27, 2026 for about USD 12.0 billion in cash, financed by an USD 11.0 billion bridge loan refinanced with bonds; Pikavation (USD 1.8 billion, PI3Ka inhibitor) and Excellergy (USD 0.9 billion, anti-IgE) bought in Q2.
- Net debt rose to USD 39.4 billion at June 30, 2026 (USD 21.9 billion at end 2025); debt/equity 1.12:1.
- About 100 projects in clinical development; Q2 approvals include Rhapsido in the EU and Japan and Itvisma in the EU; del-zota (Duchenne) submitted in the US for accelerated approval; Lutathera patents ruled invalid by a Delaware court in June 2026 (appealed).

### [Novartis Q2 2026 results conference call (transcript)](https://www.mitrade.com/insights/news/live-news/article-8-1923046-20260722)

Executive talk · Vas Narasimhan, Chief Executive Officer · 2026-07-21

- Q2 2026 was a return to growth: net sales USD 14.4 billion (+1% cc), core operating income flat at USD 5.9 billion, core margin 41.2%; growth drivers up 36% cc.
- Full-year 2026 guidance reaffirmed: net sales to grow low single digits, core operating income to decline low single digits; H2 net sales to grow mid-single digits and H2 core operating income mid to high single digits once past US Entresto generic erosion.
- New CFO Mukul Mehta: Q2 included one-time phasing worth about one point of sales and five points of core operating income (inventory shifts linked to a new SAP system rollout), reversing in H2.
- Peak sales goals kept: Kisqali USD 10 billion, Cosentyx USD 8 billion, Leqvio USD 4-5 billion-plus; Itvisma about USD 2 billion, Zolgensma plus Itvisma about USD 3 billion; ianalumab multi-billion in Sjögren's alone.
- Pipeline catalysts: Pluvicto HSPC approval expected in Q3 (eligible pool +75%), ianalumab US approval in Q3, readouts for pelacarsen, remibrutinib in MS and del-desiran (DM1) in H2; del-zota (DMD) filed for accelerated approval with launch expected H1 2027.
- M&A stance unchanged: steady deals mostly under USD 2 billion upfront, selectively larger ones like Avidity; "We don't need to do anything larger than that."
- Capital returns: USD 9.1 billion dividends and USD 2.1 billion buybacks in H1; USD 5.6 billion left in the USD 10 billion programme, to be completed by end of 2027.
- Cost focus on SG&A and third-party spend "upwards of $10 billion"; radioligand therapy network over 880 US sites and over 650 ex-US.

### [Novartis CEO on the Future of Medicine - a16z interview with Jorge Conde](https://www.youtube.com/watch?v=SAtToJulMKQ)

Podcast · Vas Narasimhan, Chief Executive Officer · 2026-03-13

- Narasimhan (CEO since January 2018) presents Novartis as a 250-year-old former conglomerate turned "pure play medicines company": about 300 million patients, over 100 countries, roughly USD 55 billion in sales, "nearing a 300 billion market cap".
- Exiting consumer health (GSK JV), spinning off Alcon and Sandoz and selling the Roche stake turned one company into four; "we lo unlocked almost $180 billion dollars of value" and fixed a "strategic mis allocation of capital"; it took six years.
- No plan to re-diversify into consumer health; consumer platforms and direct-to-patient channels are seen only as ways to "augment the core".
- Platforms: cell and gene therapy, RNA (siRNA called a mature platform; he expects a single yearly injection covering several cardiovascular targets within 5-7 years) and radioligand therapy (PSMA drug over USD 2 billion in sales, 99.9% on-time dose delivery, eight or nine lutetium projects in the clinic).
- Cell therapy for autoimmune disease ("immune reset") is a coming "renaissance", with four pivotal studies and about six more early programmes; gene therapy beyond Zolgensma is still unproven in his view.
- AI: an enabler across R&D, expected to take 7-10 years to show in approvals; aims to cut 2-4 years off 12-14-year timelines and raise success rates; partners Isomorphic Labs; 3,000 scientists on Palantir Foundry; he uses agents trained on past R&D decisions.
- China's biotech speed (first-in-human approval under a month) should push US reform of FDA staffing, IRB and contracting rather than blocking access to Chinese innovation.
- Advice to biotech founders: intellectual honesty on fit, "killer experiments", and much more investment in CMC (manufacturing) work.

## Questions about Novartis

### What does Novartis do?

Novartis is an innovative medicines company that researches, develops, manufactures and sells pharmaceutical products in oncology, immunology, neuroscience and cardiovascular, renal and metabolic diseases.

### What is Novartis' revenue?

Net sales from continuing operations were USD 54.5 billion in 2025, up 8%, with net income of USD 14.0 billion. H1 2026 net sales were USD 27 521 million.

### How many employees does Novartis have?

Novartis employed 75 267 full-time equivalents at December 31, 2025.

### Who leads Novartis?

Vas Narasimhan is CEO and Giovanni Caforio is Chair; Mukul Mehta presented the Q2 2026 results as CFO.

### What is Novartis' strategy?

Three priorities: deliver high-value medicines to accelerate growth, embed operational excellence to deliver returns, and strengthen foundations including AI capabilities, with a 5-6% (cc) annual sales growth outlook through the end of the decade.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
